U.S. Renal Care was founded in 2000 and serves more than 25,000 patients in 335 dialysis facilities in 32 states and the Territory of Guam. We have a unique business model, developing and operating dialysis centers in joint venture partnerships with leading local nephrologists.
At our core, we exist to serve our patients. In fact, we like to say that we are inspired by our patients. We do our best to provide compassionate care, where and when patients need it.
We wouldn’t be a leading dialysis provider without our leadership team. Each team member brings decades of healthcare and business experience to their roles.
For career opportunities: https://www.usrenalcare.com/about/careers.html
At our core, we exist to serve our patients. In fact, we like to say that we are inspired by our patients. We do our best to provide compassionate care, where and when patients need it.
We wouldn’t be a leading dialysis provider without our leadership team. Each team member brings decades of healthcare and business experience to their roles.
For career opportunities: https://www.usrenalcare.com/about/careers.html
Location: United States, Texas, Plano
Employees: 1001-5000
Phone: +1 214-736-2700
Founded date: 2000
Investors 7
Mentions in press and media 14
| Date | Title | Description |
| 26.08.2026 | Alebund Pharmaceuticals Announces 2026 Interim Results | SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated ... |
| 06.05.2026 | Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia | SHANGHAI, May 6, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal... |
| 17.03.2026 | R1 Therapeutics: $77.5 Million Raised To Advance Kidney Disease Treatment | R1 Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, has launched with an oversubscribed $77.5 million Series A financing to advance a first-in-class treatment for hyperphosphatemia in patients with chronic... |
| 17.03.2026 | Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 | AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, an... |
| 17.03.2026 | R1 Therapeutics Raises $77.5M in Series A Funding | R1 Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $77.5M in Series A funding. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, with participation from Curie.Bio, SymBiosis, and ... |
| 11.11.2025 | Vexev's VxWave System Successfully Meets Clinical Endpoints in Landmark Study Evaluating Robotic Ultrasound Scanning for Mapping Vascular Access at U.S. Renal Care Dialysis Clinics | VxWave Ultrasound Imaging System demonstrated 94% scanning success rate and 100% data adequacy rate for vascular access creation strategies in CANSCAN trial New insights into vascular anatomy made possible by standardized image acquisition ... |
| 30.07.2025 | Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis Clinics | CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging System The VxWave Ultrasound Imaging System potentially provides important insights into vascular access, ... |
| 01.02.2025 | Renal Support Network's 26th Annual Renal Prom will Be a Party to Remember | RSN’s 26th Annual Renal Prom will Be Night to Remember An Inspiring Evening of Joy, Connection, and Support for People Who Have Kidney Disease GLENDALE, Calif., Jan. 31, 2025 /PRNewswire-PRWeb/ -- The Renal Support Network (RSN) is excited ... |
| 30.09.2022 | Kidney Dialysis Centers Market is Valued at USD 150592.30 Million at a CAGR of 5.73% During the Forecast Period 2028 | Kidney Dialysis Centers Market DBMR analyses that the kidney dialysis centers market which was USD 96431.05 million in 2021, would rocket up to USD 150592.30 million by 2029 PUNE, MAHARASHTRA, INDIA, September 30, 2022 /EINPresswire.com/ --... |
| 03.08.2021 | Denver Video Production Company Picks Up Two More Telly Wins | Telideo Productions We’ve received so much feedback on the video, and it has really become an impactful educational tool as we talk to patients about home care DENVER (PRWEB) August 03, 2021 Telideo Productions, Inc., a Denver-based video m... |
Show more